<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153462</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-109</org_study_id>
    <nct_id>NCT03153462</nct_id>
  </id_info>
  <brief_title>Axicabtagene Ciloleucel Expanded Access Study</brief_title>
  <acronym>ZUMA-9</acronym>
  <official_title>A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite, A Gilead Company</source>
  <brief_summary>
    <textblock>
      A multicenter, open-label expanded access protocol for the treatment of subjects with
      relapsed/refractory large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Relapsed/Refractory Diffuse Large B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Primary Mediastinal B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Transformed Follicular Lymphoma</condition>
  <condition>Relapsed/Refractory High-Grade B-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>Axicabtagene Ciloleucel and A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed large B-cell lymphoma, including the following types:

               1. DLBCL, not otherwise specified

               2. Primary mediastinal large B-cell lymphoma

               3. High-grade B-cell lymphoma

               4. DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL)

          2. Relapsed or refractory disease, defined as one or more of the following:

               1. No response to first-line therapy (primary refractory disease); subjects who are
                  intolerant to first-line therapy chemotherapy are excluded OR

               2. No response or relapse to second or greater lines of therapy OR

               3. Relapsed after ASCT

          3. Subjects must have received adequate prior therapy including at a minimum:

               1. anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20
                  negative, and

               2. an anthracycline containing chemotherapy regimen;

          4. No evidence, suspicion, and/or history of central nervous system (CNS) involvement of
             lymphoma

          5. Age 18 or older

          6. Eastern cooperative oncology group (ECOG) performance status of 0 or 1

          7. Absolute neutrophil count ANC ≥1000/μL

          8. Platelet count ≥75,000/μL

          9. Absolute lymphocyte count ≥100/μL

         10. Adequate renal, hepatic, pulmonary and cardiac function defined as:

               1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min

               2. Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤2.5 upper
                  limit of normal (ULN)

               3. Total bilirubin ≤1.5 mg/dL, except in subjects with Gilbert's syndrome.

               4. Cardiac ejection fraction ≥ 50% and no evidence of pericardial effusion within
                  180 days provide the subject did not receive an anthracycline based treatment or
                  experience a cardiac event or change in performance status

               5. No clinically significant pleural effusion

               6. Baseline oxygen saturation &gt;92% on room air

         11. Cohort 2 inclusion criteria: Subjects whose commercial manufacture of axicabtagene
             ciloleucel did not meet commercial release specification(s)

        Exclusion Criteria:

          1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g.
             cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3
             years

          2. History of allogeneic stem cell transplantation (SCT)

          3. Prior CD19 targeted therapy

          4. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy

          5. History of severe, immediate hypersensitivity reaction attributed to aminoglycosides

          6. Presence or suspicion of fungal, bacterial, viral, or other infection that is
             uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple
             urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if
             responding to active treatment and after consultation with the Kite Pharma Medical
             Monitor

          7. History of human immunodeficiency virus (HIV) infection or acute or chronic active
             hepatitis B or hepatitis C infection. Subjects with a history of hepatitis infection
             must have cleared their infection as determined by standard serological and genetic
             testing per current Infectious Diseases Society of America (IDSA) guidelines

          8. History or presence of primary CNS lymphoma and/or CNS disorder such as seizure
             disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any
             autoimmune disease with CNS involvement

          9. Cohort 2 exclusion criteria: Any medical condition that, deemed by the investigator,
             may interfere with assessment of safety or efficacy of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>William Go, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-KITE</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Julianna Craig</last_name>
      <email>jkcraig@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Scott</last_name>
      <email>matthew.scott@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linda Schroeder</last_name>
      <email>lschroed@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Reidell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Rocchio</last_name>
      <email>michaelj_rocchio@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristin Arends</last_name>
      <email>arends.kristen@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6840</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Blumel</last_name>
      <phone>402-559-9183</phone>
      <email>sblumel@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicole Szuminski</last_name>
      <email>nicole.szuminski@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sherry Adkins</last_name>
      <email>sadkins@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Liliana Vallejo</last_name>
      <email>lnvallejo@mdanderson.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

